Mean corpuscular volume in *HFE* p.C282Y/p.H63D compound heterozygotes with high

iron phenotypes: clinical and laboratory associations

Running title: MCV in *HFE* p.C282Y/p.H63D compound heterozygotes

James C. Barton[1,2], J. Clayborn Barton[2], and Ronald T. Acton[2,3]

[1] Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA

[2] Southern Iron Disorders Center, Birmingham, Alabama, USA

[3] Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama,

USA

James C. Barton (corresponding author): bartonjames336@gmail.com; ORCID 0000-0003-2876-

8276

J. Clayborn Barton: jbarton205@gmail.com; ORCID 0000-0002-2646-4466

Ronald T. Acton: rtakma@bellsouth.net; ORCID 0000-0002-8586-6887

Abstract

Background: Variables that influence mean corpuscular volume (MCV) in *HFE* p.C282Y

(rs1800562)/p.H63D (rs1799945) compound heterozygotes are inadequately defined.

Methods: We retrospectively studied self-reported non-Hispanic white adult compound

heterozygotes with transferrin saturation (TS) >50% and serum ferritin (SF) >300 µg/L (men) or

TS >45% and SF >200 µg/L (women) who participated in primary care-based screening. In post-

screening evaluations, we excluded participants with anemia, pregnancy, or medication use that

increases MCV. We defined heavy alcohol intake as >28 g/d men and >14 g/d women. We

determined associations of MCV with 11 clinical and laboratory variables.

Results: There were 74 participants (37 men, 37 women) of mean age 59±12 (SD) y. Mean

screening TS and SF were 65±13% and 529±169 µg/L (men) and 59±14% and 376±195 µg/L

(women). Post-screening values did not differ significantly. Mean MCV was 95.7±4.0 fL. There

was a negative correlation of MCV with body mass index (p=0.0488) and positive correlations of

MCV with age (p=0.0098), daily heme iron intake (p=0.0333), and daily alcohol intake

(p=0.0113). Mean MCVs of 19 participants with and 55 without heavy alcohol intake were

97.8±3.8 g/d and 95.0±3.9 g/d, respectively; p=0.0074). Linear regression on MCV confirmed

positive associations with age (p=0.0064) and daily alcohol intake (p=0.0151). MCV was not

significantly associated with sex, diabetes, daily intakes of non-heme and supplemental iron,

swollen or tender 2nd/3rd metacarpophalangeal joints, TS, or SF.

Conclusion: MCV in *HFE* p.C282Y/p.H63D compound heterozygotes with high iron

phenotypes is positively associated with age and daily alcohol intake, after adjustment for other

variables.

Introduction

HFE, the homeostatic iron regulator (chromosome 6p22.2),[1][2] encodes the cell surface glycoprotein HFE, an upstream regulator of the hepatic hormone hepcidin (*HAMP*, chromosome 19q13.12), the central controller of iron homeostasis.[3] In persons of European descent, the most common *HFE* missense mutations are p.C282Y (rs1800562) and p.H63D (rs1799945).[4] The estimated prevalence of p.C282Y/p.H63D compound heterozygotes in non-Hispanic white adults in North America is 1 in 49.[5] In persons of European descent in the United Kingdom, the estimated prevalence of p.C282Y/p.H63D compound heterozygotes is 1 in 31.[4]

Mean corpuscular volume (MCV) is the average size of red blood cells.[6] In Western Australia, mean MCVs of *HFE* p.C282Y/p.H63D compound heterozygotes were significantly higher than those of subjects with neither p.C282Y nor p.H63D (*HFE* wt/wt) but were not abnormally elevated.[7][8] In contrast, the mean MCVs of referred p.C282Y/p.H63D compound heterozygotes in Alabama[9] and the Netherlands[10] and corresponding wt/wt control subjects did not differ significantly. In genome‐wide association studies of adults of European descent, there were positive statistical associations between MCV and p.C282Y[11][12][13] and p.H63D,[11] although HFE protein is not expressed in erythroid colonies.[14] We found no comprehensive study of the relationships between MCV and clinical and laboratory variables in adults with p.C282Y/p.H63D compound heterozygosity.

We performed a retrospective study of 74 adult self-reported non-Hispanic white *HFE* p.C282Y/p.H63D compound heterozygotes who 1) had both elevated TS and elevated SF in a population screening program[15] and 2) did not have anemia, report pregnancy, or use

medications that increase MCV. The aim of this study was to define the relationships between

MCV and the following clinical and laboratory variables: age, sex, BMI, diabetes, daily intakes

of heme, non-heme, and supplemental iron, daily intakes of alcohol, swollen or tender 2nd/3rd

metacarpophalangeal (MCP) joints, TS, and SF. We compare the present observations with those

of previously reported hemochromatosis and population cohorts and propose the clinical

relevance of the present results.

Methods

Ethics approval statement

The Hemochromatosis and Iron Overload Screening (HEIRS) Study, conducted by the National

Heart, Lung, and Blood Institute and the National Human Genome Research Institute, in

accordance with the principles of the Declaration of Helsinki, evaluated diverse aspects of

hemochromatosis, iron overload, and iron-related disorders in a primary care-based sample of

101,168 adults enrolled during the interval 2001-2002 at four Field Centers in the U.S. and one

in Canada.[5 15 16]

Local Institutional Review Boards of the HEIRS Study Coordinating Center (Wake Forest

University Institutional Review Board, Wake Forest University), the HEIRS Study Central

Laboratory (University of Minnesota Institutional Review Board, University of Minnesota), and

the HEIRS Study Field Centers (Medical Institutional Review Board, Howard University; UAB

Institutional Review Board for Human Use, University of Alabama at Brimingham; University of

California Irvine Institutional Review Board, University of California Irvine; Committee for the

Protection of Human Subjects/Institutional Review Board, University of Oregon in collaboration

with the University of Hawaii Biomedical Institutional Review Board, University of

Hawaii/Honolulu; and London Health Sciences Centre Research Institute, London Health

Sciences Centre) gave ethical approvals of the Study protocol that is described in detail

elsewhere.[5 15 16]

Participant consent statement

HEIRS Study participants ≥ 25 years of age were recruited from outpatient facilities affiliated

with the Field Centers and gave written informed consent for screening and post-screening

evaluation.[5][15][16] The HEIRS Study informed consent forms, not available as public documents,

were used during the participant recruitment phase of the Study (2001-2002). Each of the Field

Centers in North America used an Institutional Review Board-approved consent form tailored to

its specific institution.[5][15][16]

Primary care-based screening

The HEIRS Study recruited participants from public and private primary care offices in

ambulatory clinics, a health maintenance organization, and diagnostic blood collection centers

affiliated with five Field Centers.[5] Ninety-eight percent of self-reported non-Hispanic white

participants were recruited at Field Centers in Alabama, California, Ontario, and

Oregon/Hawaii.[17] Laboratory testing at screening included only TS and SF phenotyping and

HFE p.C282Y and p.H63D allele-specific genotyping.[5] p.C282Y/p.H63D compound

heterozygosity was identified in 908 of 44,082 non-Hispanic white adult screening participants

(2.06% [95% confidence interval (CI): 1.93, 2.91]).[17] Medical histories were not compiled and

physical examinations were not performed at primary care-based screening.

Post-screening evaluation attendees

Invitations to attend post-screening evaluations were extended to all 78 participants with *HFE*

p.C282Y/p.H63D compound heterozygosity whose screening TS and SF values were elevated

(TS >50% and SF >300 μg/L for men; TS >45% and SF >200 μg/L for women).[15][18] Post-

screening evaluation attendees included 77 of the 78 invitees (39 men, 38 women). We excluded

two men and one woman because they had anemia (hemoglobin (Hb) <130 g/L (men) and <120

g/L (women), pregnancy, or medication use that increased MCV.[19] The cohort for analysis

consisted of 74 participants (37 men, 37 women).

Post-screening evaluations

Evaluations included the following: 1) questionnaires completed by participants that addressed

medical histories and medications;[18] 2) University of Hawaii Multiethnic Dietary

Questionnaires;[18 20] 3) focused physical examinations performed by HEIRS Study physicians;[18]

and 4) laboratory testing of blood specimens.[18] The median interval between primary care-based

screening and post-screening evaluations was eight months.[18]

Medical history questionnaires

We defined reports of diabetes as affirmative responses to this question: "Have you ever been

told you have diabetes?" We defined reports of cirrhosis as affirmative responses to this question:

"Ever told that you have/had cirrhosis?"

Dietary questionnaires

Analyses of Multiethnic Dietary Questionnaires at the University of Hawaii provided estimates

of the average daily intakes of dietary iron, supplemental iron, and alcohol for the previous

year.[18 20] The dietary iron attributed to intakes of meat, fish, and poultry was classified as heme

iron and other dietary iron as non-heme iron. Iron intakes were expressed as mg/d. Alcohol

intakes were expressed as g/d. We defined heavy alcohol intake as the average intake of more

than 14 standard drinks per week (> 28 g/d) for men and more than 7 standard drinks per week

(> 14 g/d) for women.[21]

Physical examinations

We used Quetelet's formula (kg/m^2) to measure body mass index (BMI).[22] Physicians recorded

the presence or absence of swelling or tenderness of the 2nd/3rd metacarpophalangeal (MCP)

joints.[18]

Laboratory testing

Blood samples for post-screening testing were obtained after an overnight fast. All participants

were tested for *HFE* genotype confirmation, complete blood count, TS, and SF.[5] Serum alanine

aminotransferase (ALT) and aspartate aminotransferase (AST) levels were available in 46

participants (62.2%). All testing was performed at the HEIRS Study Central Laboratory

(Fairview-University Medical Center Clinical Laboratory, University of Minnesota, Fairview,

MN, USA).[15][18]

Markers of advanced hepatic fibrosis or cirrhosis

We calculated fibrosis-4 (FIB-4) indices[23] and AST-to-platelet ratio indices (APRI)[24] as markers

of advanced hepatic fibrosis or cirrhosis risk in the 46 participants (62.2%; 25 men, 21 women)

for whom the requisite data were available. We classified risks with FIB-4 as: low (FIB-4 < 1.3);

intermediate (FIB-4 1.3 - 2.67); and high (FIB-4 > 2.67).[23] We classified risks with APRI as: low

(APRI < 0.05); intermediate (APRI 0.5 - 1.5); and high (APRI > 1.5).[24] We also compiled

participant reports of cirrhosis diagnoses.

Statistics

The dataset for analyses consisted of complete observations on 74 participants (37 men, 37

women) except FIB-4 and APRI indices (25 men, 21 women). Kolmogorov-Smirnov testing

demonstrated that age, BMI, daily intake of heme iron, TS, SF, and MCV data did not differ

significantly from those that are normally distributed. We displayed these data as means $\pm$ 1

standard deviation (SD) and compared means using the Student's t test for unpaired samples

(two-tailed). We displayed other continuous data as medians (ranges) and compared medians

using the Mann-Whitney U test (two-tailed). We compared binary data using Fisher's exact test

(two-tailed). We computed associations of MCV with available continuous variables using

Pearson's correlation (two-tailed) or Spearman's rank correlation (two-tailed) for paired data, as

appropriate.

We evaluated these 11 independent variables for suitability in a multiple linear regression on

MCV: age, BMI, sex, diabetes, intakes of heme, non-heme, and supplemental iron and alcohol,

swollen or tender 2nd/3rd MCP joints, TS, and SF. We deleted sex because it was significantly

associated with SF in a Bonferroni-corrected correlation matrix. A preliminary regression on

MCV using the remaining variables revealed low standardized beta coefficients (beta) and high

values of p for BMI, diabetes, non-heme iron intake, swollen or tender 2nd/3rd MCP joints, TS,

and SF. Thus, we excluded these independent variables. We report the contributions of

significant remaining independent variables to the final regression as beta and the proportion of

variance in MCV explained by the independent variable(s) as R^2.

We used Excel® 2022 (Microsoft Corp., Redmond, WA, USA) and GraphPad Prism 8® (2018;

GraphPad Software, San Diego, CA, USA). We defined $p < 0.05$ to be significant.

Results

Characteristics of 74 *HFE* p.C282Y/p.H63D compound heterozygotes

185 There were 37 men and 37 women of mean age of 59 ± 12 y. Respective mean TS and mean SF

186 values in men and women in screening and post-screening evaluations did not differ significantly

187 (Table 1). Mean MCV was 95.7 ± 4.0 fL. Mean SF and Hb were higher in men (Table 2). Nine

188 participants (12.2%; 4 men, 5 women) had MCV ≥ 100.0 fL.

190 **Table 1.** Iron phenotypes in 74 *HFE* p.C282Y/p.H63D compound heterozygotes[a]

Men (n = 37)	Screening	Post-screening evaluation	Value of p
Mean transferrin saturation, % ± 1 SD	65 ± 13	58 ± 17	0.0692
Mean serum ferritin, µg/L ± 1 SD	529 ± 169	531 ± 170	0.9684
Women (n = 37)			
Mean transferrin saturation, % ± 1 SD	59 ± 14	53 ± 12	0.0594
Mean serum ferritin, µg/L ± 1 SD	376 ± 195	366 ± 201	0.8316

191 [a] SD, standard deviation

193 **Table 2.** *HFE* p.C282Y/p.H63D compound heterozygotes in post-screening evaluations[a]

Variable	Men (n = 37)	Women (n = 37)	Value of p
Mean age, y (SD)	57 ± 13	62 ± 12	0.0606
Mean body mass index, kg/m^2 (SD)	28.7 ± 5.0	28.0 ± 5.2	0.5405
Diabetes reports, % (n)	24.3 (6)	5.4 (2)	0.2611
Mean heme iron intake, mg/d (SD)	2.4 ± 1.4	1.9 ± 1.0	0.0549
Median non-heme iron intake, mg/d (range)	12.3 (4.2, 34.9)	12.2 (4.3, 43.7)	0.4822
Median supplemental iron intake, mg/d (range)	3.9 (0, 40.5)	3.9 (0, 40.5)	0.6892
Median alcohol intake, g/d (range)	5.7 (0, 60.9)	5.7 (0, 55.8)	0.7949
Swollen or tender 2nd/3rd MCP joints, % (n)	5.4 (2)	5.4 (2)	~1.0000
Mean transferrin saturation, % (SD)	58 ± 17	53 ± 12	0.1197
Mean serum ferritin, µg/L (SD)	531 ± 170	366 ± 201	0.0003
Mean hemoglobin, g/L	155 ±8	139 ± 9	< 0.0001
Mean corpuscular volume, fL (SD)	95.5 ± 4.0	96.0 ± 4.1 fL	0.6087

[a] MCP, metacarpophalangeal; SD, standard deviation

Markers of advanced hepatic fibrosis

High-risk FIB-4 indices were observed in five of 46 participants (10.9%), none of whom had a

high-risk APRI (Table 3). There was no significant difference in mean MCV by low,

intermediate, or high risk FIB-4 or APRI classification (Table 3). One woman reported that she

was diagnosed with cirrhosis, although both her FIB-4 and APRI risks were classified as

intermediate.

Table 3. Hepatic fibrosis risk in 46 *HFE* p.C282Y/p.H63D compound heterozygotes[a]

	Low risk, % (n)	Intermediate risk, % (n)	High risk, % (n)	Value of p
FIB-4[b]	56.5 (26)	32.6 (15)	10.9 (5)	-
Mean MCV, fL (SD)	95.7 ± 3.5	96.3 ± 5.6	97.0 ± 5.1	0.8204[d]
APRI[c]	78.3 (36)	21.7 (10)	0 (0)	-
Mean MCV, fL (SD)	96.4 ± 4.0	94.8 ± 5.5	-	0.3140[e]

[a] APRI, AST-to-platelet ratio index; FIB-4, fibrosis-4 index; MCV, mean corpuscular volume; SD,

standard deviation

[b] low risk (FIB-4 < 1.3); intermediate risk (FIB-4 1.3 - 2.67); and high risk (FIB-4 > 2.67).

[c] low risk (APRI < 0.5); intermediate risk (APRI 0.5 - 1.5); and high risk (APRI > 1.5).

[d] One-way ANOVA p test.

[e] Unpaired Student t test (two-tailed).

MCV correlations with continuous variables

There were significant positive correlations of MCV with age (Fig. 1, Table 4), daily heme iron

intake (Table 4), and daily alcohol intake (Fig. 2, Table 4), and a significant negative correlation

of MCV with BMI (Table 4).

Table 4. Correlations of mean corpuscular volume in 74 *HFE* p.C282Y/p.H63D compound

heterozygotes

Variable	Pearson's coefficient r	Spearman's coefficient *r*	Value of p[a]
Age, y	0.2983	-	0.0098[a]
Body mass index, kg/m^2	−0.2299	-	0.0488
Heme iron intake, mg/d	−0.2478	-	0.0333
Non-heme iron intake, mg/d	-	−0.0604	0.6092
Supplemental iron intake, mg/d	-	0.0742	0.5300
Alcohol intake, g/d	-	0.2860	0.0135[b]
Transferrin saturation, %	0.0667	-	0.5723
Serum ferritin, µg/L	−0.0403	-	0.7296

217 [a] See Figure 1.

218 [b] See Figure 2.

Figure 1. Pearson's correlation of mean corpuscular volume vs. age in 74 *HFE* p.C282Y/p.H63D compound heterozygotes with high iron phenotypes (r_{74} = 0.2983; p = 0.0098).

Figure 2. Spearman's rank correlation of mean corpuscular volume vs. daily alcohol intake in 74 *HFE* p.C282Y/p.H63D compound heterozygotes with high iron phenotypes (r_{74} = 0.2860; p = 0.0135).

228 **Mean MCV and binary variables**

229 Mean MCV did not differ significantly between men and women or between participants with

230 and without diabetes reports or swollen or tender 2nd/3rd MCP joints (Table 5).

232 **Table 5.** Mean corpuscular volume in 74 *HFE* p.C282Y/p.H63D compound heterozygotes[a]

Variable	Mean MCV, fL ± SD with variable (n)	Mean MCV, fL ± SD without variable (n)	Value of p
Male sex	95.5 ± 4.0 (37)	96.0 ± 4.1 (37)	0.6087
Diabetes reports	94.6 ± 3.3 (8)	95.8 ± 4.2 (66)	0.4045
Swollen or tender 2nd/3rd MCP joints	97.0 ± 5.5 (4)	95.6 ± 4.0 (70)	0.6768

[a] MCP, metacarpophalangeal; MCV, mean corpuscular volume; SD, standard deviation

MCV and heavy alcohol intakes

The mean MCV of the 19 participants (10 men, 9 women) with heavy alcohol intakes was

greater than the mean MCV of the other 55 participants (97.8 ± 3.8 vs. 95.0 ± 3.9, respectively; p

= 0.0074). Four men and two women with heavy alcohol intakes had MCV ≥ 100 fL.

Regression on MCV

Multiple linear regression on MCV using the independent variables age, daily heme iron intake,

and daily alcohol intake revealed positive associations with age (p = 0.0064; beta 0.3055) and

daily alcohol intake (p = 0.0151; beta 0.2707). The R^2 (adjusted R^2) was 0.1622 (0.1386).

ANOVA p of this regression was 0.0019.

Discussion

The novel findings of this study of 74 *HFE* p.C282Y/p.H63D compound heterozygotes with elevated screening TS and SF are that MCV was significantly associated with both age and daily alcohol intake after adjustment for other variables. An unexpected finding is that MCV was not significantly associated with TS, in contrast to observations in p.C282Y homozygotes.[9 25 26 27]

Increasing MCV of the present *HFE* p.C282Y/p.H63D compound heterozygotes was associated with increasing age. MCV also increased with age in post-screening p.C282Y homozygotes[27] and English adults in primary care venues.[28] Increasing age[29] and MCV[30] are inversely related to leukocyte telomere lengths (LTLs). In a Mendelian randomization study, an increase of one standard deviation in genetically influenced telomere length decreased MCV significantly.[31] In another study, mean LTL in p.C282Y homozygotes with and without elevated iron phenotypes did not differ significantly.[32] These observations suggest that genetic determinants of telomere length,[31] not *HFE* genotypes or iron phenotypes, account in part for the age-related increase in MCV we observed in the present p.C282Y/p.H63D compound heterozygotes.

There was a moderate negative correlation of MCV with BMI in this study, although MCV was not significantly associated with BMI after adjustment for other variables. In self-reported healthy subjects aged > 18 y in the 2011-2016 National Health and Nutrition Examination Survey, there was a weak negative association of MCV with BMI.[33]

Mean MCV of the present *HFE* p.C282Y/p.H63D compound heterozygotes with and without diabetes reports did not differ significantly. The mean MCV of Scottish adults with diabetes was

significantly higher than that of control subjects.[34] In contrast, the mean MCV of Indian adults

with type 2 diabetes was significantly lower than that of control subjects.[35]

There was a weak positive correlation of MCV with daily heme iron intake in this study,

although MCV was not significantly associated with daily heme iron intake after adjustment for

other variables. In Dutch blood and plasma donors, MCV was positively associated with heme

iron intakes in men but not in women.[36]

MCVs of the present *HFE* p.C282Y/p.H63D compound heterozygotes were positively associated

with daily alcohol intakes. The mean MCV of Australian men and women with any p.C282Y

genotype also increased with alcohol intake after adjustment for age.[37] In the same study, neither

p.C282Y nor p.H63D alone predisposed to moderate or heavy alcohol intake.[37] In British adults

without anemia, MCV also increased with alcohol intake, but there was no interaction between

alcohol consumption and allelic variants associated with MCV.[38]

The present *HFE* p.C282Y/p.H63D compound heterozygotes were invited to attend post-

screening evaluations because their screening TS and SF values were elevated.[15] Heavy alcohol

intake occurred in 25.7% of the present compound heterozygotes, whereas heavy alcohol intake

occurs in ~6.5% of non-Hispanic white adults in the U.S.[21] Alcohol intake was excessive in

38.9% of Australian p.C282Y/p.H63D compound heterozygotes with hemochromatosis and SF >

1000 µg/L.[39] Excessive alcohol intake increases TS[40][41] and SF.[42] The clinical significance of

these observations is that alcohol intake is significantly associated with elevated MCV in

p.C282Y/p.H63D compound heterozygotes with both elevated TS and elevated SF.

Swollen or tender 2nd/3rd MCP joints were not associated with MCV and macrocytosis in this

study, in contrast to observations in *HFE* p.C282Y homozygotes.[27 43] The prevalence of swollen

or tender 2nd/3rd MCP joints in the present p.C282Y/p.H63D compound heterozygotes was

lower than that of post-screening participants with p.C282Y homozygosity (5.4% and 14.4%,

respectively; p = 0.0246).[27]

It was unexpected that MCVs in the present *HFE* p.C282Y/p.H63D compound heterozygotes

were not significantly associated with TS, in contrast to the positive associations between MCV

and TS in p.C282Y homozygotes.[9 26 27] Mean TS is significantly lower in untreated

p.C282Y/p.H63D compound heterozygotes than untreated p.C282Y homozygotes.[5] This suggests

that the mean TS in p.C282Y/p.H63D compound heterozygotes is insufficient to increase the

uptake of transferrin-bound iron by immature erythroid cells, increase Hb synthesis, and thereby

increase MCV.[9]

Limitations of this study include the lack of observations of *HFE* p.C282Y/p.H63D participants

without both elevated TS and SF and of participants aged < 25 y.[5] The HEIRS Study did not

measure serum levels of vitamin B12 or folate, although none of the present subjects had anemia

and deficiencies of these micronutrients were uncommon causes of macrocytosis in another

primary care cohort.[44] More than three-quarters of the variance in MCV values in the present

linear regression is attributable to variables we did not analyze, especially non-*HFE* genetic

factors.[11 31 38] Measuring iron stores using quantitative phlebotomy or liver specimens obtained

by biopsy and performing clinical evaluations for cirrhosis were beyond the scope of the cross-

sectional HEIRS Study.

The present post-screening examination invitation criteria of both elevated TS and elevated SF

may have preferentially although unintentionally selected p.C282Y/p.H63D compound

heterozygotes with heavy daily alcohol intakes. None of 46 participants had combination of

high-risk FIB-4 and APRI indices. It is unknown whether any of the other 28 participants

(37.8%) would have had high-risk FIB-4 and APRI indices or not, although none of them

reported a diagnosis of cirrhosis. The prevalence of documented iron overload-related disease

(including cirrhosis) was low in other cohorts of *HFE* p.C282Y/p.H63D compound

heterozygotes.[45 46] These observations suggest the prevalence of occult advanced hepatic fibrosis

or cirrhosis is also low in the present cohort and unlikely to influence the present results

significantly.

Conclusion

We conclude that MCV in *HFE* p.C282Y/p.H63D compound heterozygotes with high iron

phenotypes is positively associated with age and daily alcohol intake, after adjustment for other

variables.

Acknowledgements

Laboratory Medicine and Pathology, University of Minnesota, Minneapolis); Victor R. Gordeuk,

MD (Division of Hematology and Oncology, Department of Medicine, University of Illinois at

Chicago, Chicago); Emily Harris, PhD (Epidemiology and Genomics Research Program,

Division of Cancer Control and Population Sciences, National Cancer Institute, National

Institutes of Health, Bethesda, Maryland); Helen Harrison, RN (The Western-Fanshawe

Collaborative BScN Program, Fanshawe College, London, Ontario, Canada); Christine E.

McLaren, PhD (Department of Epidemiology, University of California, Irvine, California); and

Gordon D. McLaren, MD (Division of Hematology/Oncology, Department of Medicine,

University of California, Irvine, and Department of Veterans Affairs Long Beach Healthcare

System, Long Beach, California).

Authors' contributions

Each author contributed substantively to this study. JaCB conceived this study and its

methodology, collected data, evaluated participants in post-screening evaluations, performed

analyses, and drafted the manuscript. JClB conceived study methodology, curated data,

performed analyses, and drafted the manuscript. RTA conceived this study and its methodology,

collected data, performed analyses, curated data, and drafted the manuscript. Each author

approved the manuscript in its final form.

Competing interest statement

The authors report no conflict of interest. The authors and their respective institutions have not

received any payments or services in the past 36 months from a third party that could be

perceived to influence, or give the appearance of potentially influencing, the submitted work.

Funding statement

The National Heart, Lung, and Blood Institute and the National Human Genome Research Institute had major roles in the HEIRS Study design, data collection, data analyses, and funding, but had no role in the decision to publish the present work. The authors received additional funding from Southern Iron Disorders Center for performing data curation and analysis and manuscript composition.

Data Sharing Statement

The National Heart, Lung, and Blood Institute provides controlled access to individual participant data through the Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) (https://biolincc.nhlbi.nih.gov/studies/heirs/). Data access requires registration, evidence of local institutional review board approval or certification of exemption from institutional review board review, and completion of a data use agreement. The National Heart, Lung, and Blood Institute does not permit investigators to submit data directly to journals, related repositories, or other sources. Parties interested in obtaining the data analyzed in the present study are referred to BioLINCC.

References

1. Barton JC, Edwards CQ, Acton RT. *HFE* gene: Structure, function, mutations, and associated iron abnormalities. *Gene;*2015;**574**:179-192. doi: 10.1016/j.gene.2015.10.009

2. Girelli D, Busti F, Brissot P*, et al.* Hemochromatosis classification: update and recommendations by the BIOIRON Society. *Blood;*2022;**139**:3018-3029. doi: 10.1182/blood.2021011338

3. Ganz T. Hepcidin and iron regulation, 10 years later. *Blood;*2011;**117**:4425-4433. doi: 10.1182/blood-2011-01-258467

4. Merryweather-Clarke AT, Pointon JJ, Shearman JD*, et al.* Global prevalence of putative haemochromatosis mutations. *J Med Genet;*1997;**34**:275-278. doi: 10.1136/jmg.34.4.275

5. Adams PC, Reboussin DM, Barton JC*, et al.* Hemochromatosis and iron-overload screening in a racially diverse population. *N Engl J Med;*2005;**352**:1769-1778. doi: 10.1056/NEJMoa041534

6. Means RTJr, Glader B. Anemia: general considerations. In: Means RT Jr, Rodgers GM, Glader B et al., eds. Wintrobe's Clinical Hematology. Philadelphia: Wolters Kluwer; 2024:600-627.

7. Rossi E, Olynyk JK, Cullen DJ*, et al.* Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. *Clin Chem;*2000;**46**:162-166.

8. Rossi E, Bulsara MK, Olynyk JK, *et al.* Effect of hemochromatosis genotype and
lifestyle factors on iron and red cell indices in a community population. *Clin*
*Chem;*2001;**47**:202-208.

9. Barton JC, Bertoli LF, Rothenberg BE. Peripheral blood erythrocyte parameters in
hemochromatosis: evidence for increased erythrocyte hemoglobin content. *J Lab Clin*
*Med;*2000;**135**:96-104. doi: 10.1016/s0022-2143(00)70026-6

10. de Valk B, Witlox RS, van der Schouw YT, *et al.* Biochemical expression of
heterozygous hereditary hemochromatosis. *Eur J Intern Med;*2000;**11**:317-321. doi:
10.1016/s0953-6205(00)00111-4

11. Ganesh SK, Zakai NA, van Rooij FJ, *et al.* Multiple loci influence erythrocyte
phenotypes in the CHARGE Consortium. *Nat Genet;*2009;**41**:1191-1198. doi:
10.1038/ng.466

12. Kullo IJ, Ding K, Jouni H, *et al.* A genome-wide association study of red blood cell traits
using the electronic medical record. *PLoS One;*2010;**5**:e13011. doi:
10.1371/journal.pone.0013011

13. McLaren CE, Garner CP, Constantine CC, *et al.* Genome-wide association study
identifies genetic loci associated with iron deficiency. *PLoS One;*2011;**6**:e17390. doi:
10.1371/journal.pone.0017390

14. Feeney GP, Carter K, Masters GS, *et al.* Changes in erythropoiesis in hereditary
hemochromatosis are not mediated by HFE expression in nucleated red cells.
*Haematologica;*2005;**90**:180-187.

15. McLaren CE, Barton JC, Adams PC, *et al.* Hemochromatosis and Iron Overload
Screening (HEIRS) Study design for an evaluation of 100,000 primary care-based adults.
*Am J Med Sci;*2003;**325**:53-62. doi: 10.1097/00000441-200302000-00001

16. Hemochromatosis and Iron Overload Screening Study (HEIRS) January 2000-January
2006. Available at: https://biolincc.nhlbi.nih.gov/studies/heirs/. Accessed 16 October
2025.

17. Barton JC, Acton RT, Dawkins FW, *et al.* Initial screening transferrin saturation values,
serum ferritin concentrations, and *HFE* genotypes in whites and blacks in the
Hemochromatosis and Iron Overload Screening Study. *Genet Test;*2005;**9**:231-241. doi:
10.1089/gte.2005.9.231

18. McLaren GD, McLaren CE, Adams PC, *et al.* Clinical manifestations of
hemochromatosis in *HFE* C282Y homozygotes identified by screening. *Can J*
*Gastroenterol;*2008;**22**:923-930. doi: 10.1155/2008/907356

19. Nagao T, Hirokawa M. Diagnosis and treatment of macrocytic anemias in adults. *J Gen*
*Fam Med;*2017;**18**:200-204. doi: 10.1002/jgf2.31

20. Stram DO, Hankin JH, Wilkens LR, *et al.* Calibration of the dietary questionnaire for a
multiethnic cohort in Hawaii and Los Angeles. *Am J Epidemiol;*2000;**151**:358-370. doi:
10.1093/oxfordjournals.aje.a010214

21. Boersma, P., Villarroel, M. A., and Vahratian, A. Heavy Drinking Among U.S. Adults,
2018. Available at: https://www.cdc.gov/nchs/data/databriefs/db374-h.pdf. Accessed
September 15, 2025.

22. Eknoyan G. Adolphe Quetelet (1796-1874)--the average man and indices of obesity.

*Nephrol Dial Transplant;*2008;**23**:47-51. doi: gfm517 [pii];10.1093/ndt/gfm517 [doi]

23. Shah AG, Lydecker A, Murray K*, et al.* Comparison of noninvasive markers of fibrosis in

patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol;*2009;**7**:1104-

1112. doi: 10.1016/j.cgh.2009.05.033

24. Borroni G, Ceriani R, Cazzaniga M*, et al.* Comparison of simple tests for the non-

invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C. *Aliment Pharmacol*

*Ther;*2006;**24**:797-804. doi: 10.1111/j.1365-2036.2006.03034.x

25. McLaren CE, Barton JC, Gordeuk VR*, et al.* Determinants and characteristics of mean

corpuscular volume and hemoglobin concentration in white *HFE* C282Y homozygotes in

the Hemochromatosis and Iron Overload Screening Study. *Am J Hematol;*2007;**82**:898-

905. doi: 10.1002/ajh.20937

26. Adris N, Hazeldine S, Bentley P*, et al.* Detection of *HFE* haemochromatosis in the clinic

and community using standard erythrocyte tests. *Blood Cells Mol Dis;*2019;**74**:18-24.

doi: 10.1016/j.bcmd.2018.10.003

27. Barton JC, Barton JC, Acton RT. Factors related to mean corpuscular volume in *HFE*

p.C282Y homozygotes. *ejHaem;*2024;**6**:e1063. doi: 10.1002/jha2.1063

28. Phillips R, Wood H, Weaving G*, et al.* Changes in full blood count parameters with age

and sex: results of a survey of almost 900 000 patient samples from primary care. *Br J*

*Haematol;*2021;**192**:e102-e105. doi: 10.1111/bjh.17290

29. Frenck RW, Jr., Blackburn EH, Shannon KM. The rate of telomere sequence loss in
human leukocytes varies with age. *Proc Natl Acad Sci U S A;*1998;**95**:5607-5610. doi:
10.1073/pnas.95.10.5607

30. Kozlitina J, Garcia CK. Red blood cell size is inversely associated with leukocyte
telomere length in a large multi-ethnic population. *PLoS One;*2012;**7**:e51046. doi:
10.1371/journal.pone.0051046

31. Adams CD, Boutwell BB. A Mendelian randomization study of telomere length and
blood-cell traits. *Sci Rep;*2020;**10**:12223. doi: 10.1038/s41598-020-68786-6

32. Mainous AG, III, Wright RU, Hulihan MM, *et al.* Telomere length and elevated iron: the
influence of phenotype and *HFE* genotype. *Am J Hematol;*2013;**88**:492-496. doi:
10.1002/ajh.23438

33. Thavaraputta S, Dennis JA, Ball S, *et al.* Relation of hematologic inflammatory markers
and obesity in otherwise healthy participants in the National Health and Nutrition
Examination Survey, 2011-2016. *Proc (Bayl Univ Med Cent);*2020;**34**:17-21. doi:
10.1080/08998280.2020.1799482

34. Davidson RJ, Evan-Wong LA, Stowers JM. The mean red cell volume in diabetes
mellitus. *Diabetologia;*1981;**20**:583-584. doi: 10.1007/BF00252770

35. Basak M, Dey SK, Ghosh S*, et al.* A clinicopathological investigation on morphological
alterations of red blood cells among treated and untreated type II diabetes mellitus
patients. *Indian J Pathol Microbiol;*2025;**20**(20):1-9. doi: 10.4103/ijpm.ijpm_99_25

36.   Timmer TC, de GR, Rijnhart JJM*, et al.* Dietary intake of heme iron is associated with

481   ferritin and hemoglobin levels in Dutch blood donors: results from Donor InSight.

482   *Haematologica;*2020;**105**:2400-2406. doi: 10.3324/haematol.2019.229450

483   37.   Olynyk JK, Knuiman MW, Divitini ML*, et al.* Effects of *HFE* gene mutations and alcohol

484   on iron status, liver biochemistry and morbidity. *J Gastroenterol Hepatol;*2005;**20**:1435-

485   1441. doi: 10.1111/j.1440-1746.2005.03967.x

486   38.   Thompson A, King K, Morris AP*, et al.* Assessing the impact of alcohol consumption on

487   the genetic contribution to mean corpuscular volume. *Hum Mol Genet;*2021;**30**:2040-

488   2051. doi: 10.1093/hmg/ddab147

489   39.   Walsh A, Dixon JL, Ramm GA*, et al.* The clinical relevance of compound heterozygosity

490   for the C282Y and H63D substitutions in hemochromatosis. *Clin Gastroenterol*

491   *Hepatol;*2006;**4**:1403-1410. doi: 10.1016/j.cgh.2006.07.009

492   40.   Whitfield JB, Zhu G, Heath AC*, et al.* Effects of alcohol consumption on indices of iron

493   stores and of iron stores on alcohol intake markers. *Alcohol Clin Exp Res;*2001;**25**:1037-

494   1045.

495   41.   Kroll DS, McPherson KL, Manza P*, et al.* Elevated transferrin saturation in individuals

496   with alcohol use disorder: association with *HFE* polymorphism and alcohol withdrawal

497   severity. *Addict Biol;*2022;**27**:e13144. doi: 10.1111/adb.13144

498   42.   Milman N, Kirchhoff M. Relationship between serum ferritin, alcohol intake, and social

499   status in 2235 Danish men and women. *Ann Hematol;*1996;**72**:145-151. doi:

500   10.1007/s002770050153

43. Rehman A, Carroll GJ, Powell LW*, et al.* Arthropathy in hereditary haemochromatosis

segregates with elevated erythrocyte mean corpuscular volume. *Scand J*

*Rheumatol;*2021;**50**:139-142. doi: 10.1080/03009742.2020.1800081

44. Wymer A, Becker DM. Recognition and evaluation of red blood cell macrocytosis in the

primary care setting. *J Gen Intern Med;*1990;**5**:192-197. doi: 10.1007/BF02600531

45. Gurrin LC, Bertalli NA, Dalton GW*, et al. HFE* C282Y/H63D compound heterozygotes

are at low risk of hemochromatosis-related morbidity. *Hepatology;*2009;**50**:94-101. doi:

10.1002/hep.22972

46. Hasan SMM, Farrell J, Borgaonkar M. C282Y/H63D compound heterozygosity is a low

penetrance genotype for iron overload-related disease. *J Can Assoc*

*Gastroenterol;*2022;**5**:240-247. doi: 10.1093/jcag/gwac025

513